Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

2013555 citationsJournal Article

Authors

Shuichi Hironaka

Shinya Ueda

Toshikazu Moriwaki · Tohoku University

Taito Esaki · University of Tsukuba

Abstract

No statistically significant difference was observed between paclitaxel and irinotecan for OS. Both are reasonable second-line treatment options for advanced gastric cancer.

Topics & Keywords

Gastric Cancer Management and Outcomes Metastasis and carcinoma case studies Gastrointestinal Tumor Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 31, Issue 35, pp. 4438-4444

DOI: 10.1200/jco.2012.48.5805

Field-Weighted Citation Impact: 26.30